1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > Cardiology Point of Care Diagnostics: Products, players & outlook to 2017

Cardiology Point of Care Diagnostics: Products, players & outlook to 2017

  • September 2012
  • -
  • Espicom Business Intelligence
  • -
  • 134 pages

Despite the economic situation and many operational challenges, the POC cardiology product sector is set to achieve growth of 7.8%

The POC cardiology diagnostics market was worth over US$2 billion in 2011 and rose by 9% compared with 2010. This was driven by a growing interest in the adoption of POC technologies by both healthcare providers and patients at home, as well as the introduction of new products that enable POC testing for more applications, enhance ease-of-use and improve on current products.

POC testing can offer clear benefits over laboratory testing. As it is conducted in the presence of or near the patient, results are available much more quickly, enabling healthcare providers to act swiftly to emergencies such as heart attack and provide a diagnosis while the patient is still in the healthcare facility, speeding treatment and reducing visits to the doctor. For patients, self-testing helps users control their condition, reducing the chance of complications and improving health, while lowering the time and cost of treating complications, and the need for patients to regularly see their doctor.

There is currently much innovation in the market. Products that enable multi-parameter diagnostics using technologies such as microfluidics are a major focus, as are products for personalised medicine. For example, the first POC DNA analysis system, Spartan Bioscience’s RX CYP2C19, has European approval to help identify patients with impaired metabolism to the popular anti-blood clotting medication, clopidogrel.

This volume provides...

Market growth forecasts by sector to 2017
Evaluation of 60 companies
Detailed operating environment analysis

All major POC cardiology testing technologies are covered

Platelet function
Cardiac markers
Companion diagnostics

Products for all user groups

Physician office
Emergency room/A&E
Home testing

About the Author

This report has been researched and written by independent medical market analyst Joanne Maddox. For over 13 years she has played a pivotal role in tracking trends in medical device and equipment markets and companies. A former editor of Medical Device Companies Analysis she has also written The Global Advanced Wound Care Market to 2017; Advances in Molecular Imaging 2013; and, Telemonitoring: Challenges and Opportunities.

About the Publisher

For over 30 years Espicom Business Intelligence, a Business Monitor company, has been a leading provider of key medical device and technology data. Its experienced and knowledgeable authors are uniquely placed to produce this high-quality and thoroughly researched management report. Espicom is part of Business Monitor International.

Table Of Contents

Cardiology Point of Care Diagnostics: Products, players and outlook to 2017

POC Cardiovascular POC 2
The Role Of POC Testing in Cardiovascular Care 3
Customers of POC Cardiovascular Diagnostic Products 4
POC Cardiovascular Technologies by Customer Segment 4
Regulatory and Reimbursement Environment 5
CLIA Waiver 5
Fig 1: POC Diagnostics in Relation to the IVD Market, 2011 6
Fig 2: Percentage of POC Diagnostics Market by Product, 2011 7
Regional Perspective 7
Fig 3: Professional POC Diagnostics Market by Region, 2011 8
POC Cardiovascular Testing Market 8
POC Cardiovascular Diagnostics Market by Product Type, 2007-2011 (US$ million) 9
Fig 4: Cardiac POC Testing Market by Product, 2011 9
The Burden of Cardiovascular Disease 10
POC Diagnostics and the Economy 11
POC Diagnostics as a Disruptive Technology 12
Clinical Utility and Accuracy 12
Connectivity 13
Emerging Technologies 13
Companion Diagnostics 13
Lab-on-a-Chip Devices and Microfluidics 14
Summary: Market Drivers, Restraints and Opportunities 15
Market Leaders for Cardiovascular POC Testing Products 16
Select POC Diagnostics Companies' Sales, 2007-2011 (US$ million) 16
Merger and Acquisition Activity 17
Key POC Diagnostics Mergers and Acquisitions, 2008-2011 17
POC Cardiovascular Testing Market by Product Type, 2011-2017E (US$ million) 19
POC Cardiovascular Testing Market by Product Growth, 2008-2017E (%) 19
POC Coagulation Testing Market Dynamics 20
Fig 5: Global POC Coagulation Market, 2007-2017E (US$ million) 21
The Impact of New-Generation Anticoagulants 21
Self-Monitoring Products 23
CoaguSense's CoaguSense PT/INR Monitoring System 24
Alere's INRatio2 System 24
International Technidyne Corporation's ProTime System 24
ProTime Microcoagulation System 24
Roche's CoaguChek XS 25
Professional Use Products 25
Abbott's i-STAT System 25
i-STAT Cartridges 26
Alere's Axis-Shield Products 26
Helena Laboratories' Cascade POC System 27
Helena Laboratories' Actalyke and MAX-ACT 27
Medtronic‘s ACT Plus Automated Coagulation Timer System27
Instrumentation Laboratory's GEM PCL Plus 27
ITC's Hemochron Whole Blood Coagulation System 27
Hemochron Signature Elite and Hemochron Signature Plus Microcoagulation System 28
Hemochron Response 28
Radiometer's AQT90 FLEX Immunoassay Analyser 28
Roche's CoaguChek Systems 28
CoaguChek XS Pro 29
CoaguChek XS Plus 29
CoaguChek XS 29
CoaguChek Link 29
Products in Development 30
Bio-AMD's COAG 30
Siemens/Universal Biosensors' POC Coagulation Tests 30
Surgical Coagulation and Haemostasis Management 31
Akers Biosciences' PIFA Heparin/PF4 and PIFA PLUSS Rapid Assays 31
Haemonetics' TEG Thrombelastograph Hemostasis Analyzer 32
Medtronic's HMS PLUS Haemostasis Management System 32
Pentapharm's ROTEM delta 33
Sienco's Sonoclot Coagulation and Platelet Function Analyzers 33
Clinical Guidelines 34
Accumetrics' VerifyNow System 35
Clinical Studies 35
Helena Laboratories' Plateletworks System 36
Clopidogrel Effectiveness Assessment 36
Spartan Bioscience's Spartan RX CYP2C19 POC DNA Testing System 37
Clinical Studies 37
PROTECT Study 39
VISION Study 40
POC Testing40
Gaining Clinical Evidence41
Market Dynamics 42
Fig 6: Global POC Cardiac Marker Testing Market, 2007-2017E (US$ million) 42
POC Testing Products 43
Currently-Available Cardiac Marker POC Tests 43
Abbott's i-STAT System 44
Alfa Wassermann's ACE Clinical Chemistry Systems 45
Alere's Heart Check System 45
Alere's Triage and Clearview Products 45
Audit Diagnostics' DryLab 48
bioMerieux VIDAS and bioNexia Tests 48
Nexus Dx/Samsung's LABGEO POC Cardiovascular Analysers 48
Mitsubishi Chemical's Pathfast Immunoassay Analyzer 49
Ortho-Clinical Diagnostics' VITROS DT60 II Chemistry System 49
Radiometer's AQT90 FLEX Immunoassay Analyser 49
Randox Laboratories' Evidence Multistat 50
ReLIA Diagnostic Systems' ReLIA System 50
Response Biomedical's RAMP Platform 50
Roche Cardiac Testing Products 52
Siemens' Stratus CS Analyzer 53
Tosoh Bioscience's AIA-360 Immunoassay Analyser 53
Products in Development 54
Cholesterol Testing and Preventative Medicine 57
POC Cholesterol Testing Market Dynamics 58
Fig 7: Global POC Cholesterol Testing Market, 2007-2017E (US$ million) 59
Professional Use Products 59
Abaxis' Piccolo xpress 59
Alere's Cholestech LDX System 60
Alfa Wassermann's ACE Clinical Chemistry Systems 60
Arkray's SpotChem Dry Chemistry Analysers 61
Audit Diagnostics' Liqui-Stat System 61
Horiba ABX' Pentra Clinical Chemistry Analysers 61
Jant Pharmacal's LipidPlus Lipid Profile and Glucose Test System 61
Polymer Technology Systems' CardioChek PA 62
Miraculins' PreVu Point of Care Skin Sterol Test 62
Distribution Agreements 63
Samsung's LABGEO PT10 Clinical Chemistry Analyzer 64
Products in Development 64
Roche and Panasonic Healthcare 64
Home Testing 64
Alere's First Check Cholesterol Test 64
Akers Biosciences' Tri-Cholesterol Check 64
Chematics Chemcard Cholesterol Test 65
Infopia's Lipid Pro 65
Roche's Accutrend Plus 65
Syntron Bioresearch's Venture Total Cholesterol Test 65
Ativa Medical's POC Analyser 66
Atonomics' Atolyzer 67
Bio-AMD's MPR 67
Biosensia's RapiPlex 67
Fiomi Diagnostics (Trinity Biotech) Forecast Technology 68
MagnaBioSciences' MICT On-Site System 69
Molecular Vision 69
MycroLab 69
OPKO Health's OPKO Diagnostics Platform 70
Philips' Minicare 71
Radisens Diagnostics' POC Platform 72
T2 Biosystems' T2Dx System 72
T2Hemostasis Assay 73
Abbott 78
Recent Key Events 78
i-STAT Point-of-Care Products 78
i-STAT Cartridges79
Financial Performance 80
Abbott Point of Care Sales, 2010-2011 (US$ million) 80
Fig 8: Percentage of Abbott Point of Care Revenue by Region, 2011 80
Accumetrics 81
Recent Key Events 81
Fig 9: Accumetrics Revenue, 2005-2011 (US$ thousand) 82
VerifyNow System 82
Distribution Agreements 83
Akers Biosciences 84
Recent Key Events 84
Current Products 85
PIFA Heparin/PF4 and PIFA PLUSS Rapid Assays 85
Tri-Cholesterol Check 85
Current Alliances and Distribution Agreements 86
Al Tadawi Medical Equip/ PharmaNova Medical Equipment 86
Fisher HealthCare 86
Financial Performance 86
Akers Biosciences Operating Results, 2007-2011 (US$ thousands) 87
Fig 10: Percentage of Akers' Revenue by Product Type, 2011 87
Alere 88
Recent Key Events 89
POC Cardiology Diagnostic Products 89
Triage Cardiac Marker Tests 89
Alere Heart Check System 91
Cholestech LDX 92
INRatio2 System 92
Axis-Shield Products 92
RALS-Plus POC IT Solution 94
Alere Consumer Products 94
POC Mergers and Acquisitions 94
Axis-Shield 94
Medical Automation Systems' 94
Standard Diagnostics 95
Mologic, Jinsung Meditech, Biolinker and Long Chain International Corp 95
Zycare, Medim and Biosyn 95
ACON Laboratories' Rapid Diagnostics Assets 95
Matria Healthcare 96
BBI Holdings 96
Other Acquisitions 96
Current Alliances 97
Spartan Bioscience 97
Epocal 97
Financial Performance 97
Alere - Operating Results, 2007-2011 (US$ million) 98
Fig 11: Percentage of Alere's Revenue by Segment, 2011 98
Fig 12: Percentage of Alere's Revenue by Region, 2011 99
Alere Professional Diagnostics Operating Results, 2007-2011 (US$ million) 99
Alere Professional Diagnostics Net Sales and Services Revenue, 2007-2011 (US$ million) 99
Fig 13: Alere Professional Diagnostics Net Sales and Services Revenue by Product, 2011 100
Alere Consumer Diagnostics Operating Results, 2007-2011 (US$ million) 100
Latest Results 100
Axis Shield - Financial Performance 101
Fig 14: Axis-Shield Revenue by Business Unit, 2010 102
Fig 15: Axis-Shield Revenue by Region, 2010 102
Axis-Shield - POC Segment Operating Results, 2006-2010 (£ million) 102
Axis-Shield - POC Sales by Product Line, 2006-2010 (£ million) 103
Fig 16: Axis-Shield POC Sales by Product, 2010 103
Fig 17: Axis-Shield Afinion Sales by Region, 2010 103
bioMerieux 104
bioNexia POC Tests 104
VIDAS Tests 104
VIDAS Troponin I Ultra 104
VIDAS D-Dimer Exclusion105
VIDAS B·R·A·H·M·S PCT Test 105
Current Alliances 105
Uppsala Clinical Research Center105
Philips 105
Sysmex 106
ReLIA Diagnostic Systems 106
Roche Diagnostics 106
Brahms 106
Financial Performance 106
bioMerieux - Operating Results, 2007-2011 (EUR million) 106
Fig 18: Percentage of bioMerieux' Revenue by Product Type, 2011 107
Fig 19: Percentage of bioMerieux' Revenue by Region, 2011 107
International Technidyne Corporation 108
Products 108
ProTime Microcoagulation System 108
Hemochron Whole Blood Coagulation System 108
IRMA TRUpoint Blood Analysis System 109
AVOXimeter Whole Blood CO Oximeter and Oximeter 109
Current Alliances 110
Alere 110
Financial Performance 110
International Technidyne Operating Results, 2004-2009 (US$ million) 110
Fig 20: International Technidyne Revenue, 2000-2010 (US$ million) 111
Radiometer (Danaher) 112
Recent Key Events 112
AQT90 FLEX Immunoassay Analyser 112
AQURE POC Management System 113
Financial Performance 113
Fig 21: Radiometer - Revenue by Region, 2010 114
Response Biomedical 115
Recent Key Events 115
RAMP System 116
Cardiac Marker Tests 117
Current Alliances 117
Fisher Scientific 117
Cremascoli 117
OandD Biotech 117
Guangzhou Wondfo Biotech 118
Shionogi 118
Financial Performance 118
Response Biomedical - Operating Results, 2007-2011 (C$ thousand) 118
Response Biomedical - Product Sales by Category, 2009-2011 (C$ thousand) 119
Fig 22: Response Biomedical - Product Sales by Category, 2011 119
Response Biomedical - Revenue by Region, 2009-2011 (C$ thousand) 119
Fig 23: Response Biomedical - Revenue by Region, 2011 120
Latest Results 120
Roche Diagnostics 121
Recent Key Events 121
CoaguChek Systems 122
CoaguChek XS Pro 122
CoaguChek XS Plus 122
CoaguChek XS 122
CoaguChek Link 122
Cardiac Testing Products 123
cobas h 232 Portable Cardiac Testing Device 123
Cardiac Reader 123
TROP T Sensitive Rapid Assay 123
cobas POC IT Solution 124
Current Alliances and Contracts 124
Panasonic Healthcare 124
Eidia (Eisai) 124
Voluntis 124
Radiometer 125
bioMerieux 125
Alere 125
Dade Behring (Siemens) 125
Financial Performance 125
Roche Diagnostics Operating Results, 2010-2011 (SFr million) 126
Fig 24: Roche Diagnostics - Revenue by Product Line, 2011 126
Fig 25: Roche Professional Diagnostics - Revenue by Region, 2011 126
Latest Results 127
Siemens Healthcare 128
Recent Key Events 128
Stratus CS Acute Care Diagnostic System 128
Current Alliances and Supply Contracts 129
Universal Biosensors 129
Premier 129
Roche 129
Financial Performance 129
Latest Results130

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Cancer Diagnostics: US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers

Cancer Diagnostics: US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers

  • $ 21 100
  • Industry report
  • June 2016
  • by Venture Planning Group

VPGMarketResearch.com presents a new study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe ...

Cancer Diagnostics Market Segmentation Analysis: Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics Market Segmentation Analysis: Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21 100
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Molecular Diagnostic Analyzers and Reagents: US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers

Molecular Diagnostic Analyzers and Reagents: US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers

  • $ 15 900
  • Industry report
  • June 2016
  • by Venture Planning Group

This new seven-country study from VPGMarketResearch.com contains 1,398 pages, 194 tables, and is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.